seastar.png
SeaStar Medical Projects Multibillion-Dollar Market Potential for its Selective Cytopheretic Device in Initial Target Indications
December 11, 2024 06:30 ET | SeaStar Medical Holding Corporation
U.S. total addressable market for five initial indications is $25 to $33 billion REMINDER: Business Update Conference Call begins at 4:30 p.m. Eastern time today DENVER , Dec. 11, 2024 (GLOBE...
seastar.png
SeaStar Medical to Hold Business Update Conference Call on December 11, 2024
December 04, 2024 08:30 ET | SeaStar Medical Holding Corporation
DENVER, Dec. 04, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
seastar.png
SeaStar Medical Activates Sentara Norfolk General Hospital and Provides Enrollment Update in Adult AKI Pivotal Trial
December 03, 2024 08:30 ET | SeaStar Medical Holding Corporation
DENVER, Dec. 03, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
seastar.png
SeaStar Medical to Present at Noble Capital Markets’ NobleCon20 on December 4, 2024
November 26, 2024 08:00 ET | SeaStar Medical Holding Corporation
DENVER, Nov. 26, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
logo.png
Autonomix Medical, Inc. Announces Pricing of $9.0 Million Underwritten Public Offering
November 22, 2024 09:15 ET | Autonomix Medical, Inc.
THE WOODLANDS, TX, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted...
seastar.png
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Support SeaStar Medical’s Proposals to Ratify the Issuance of Shares and to Reduce the Number of Authorized Shares
November 22, 2024 08:30 ET | SeaStar Medical Holding Corporation
SeaStar Medical urges stockholders to vote FOR all proxy proposals prior to the Special Meeting of Stockholders to be held November 26, 2024 DENVER, Nov. 22, 2024 (GLOBE NEWSWIRE) -- SeaStar...
logo.png
Autonomix Medical, Inc. Reports Second Quarter Fiscal Year 2025 Financial Results and Provides a Corporate Update
November 11, 2024 08:00 ET | Autonomix Medical, Inc.
Ongoing proof-of-concept (PoC) clinical trial in pain associated with pancreatic cancer; Preliminary results demonstrate 100% of the lead-in patient responder group went to zero opioid use at 4-6...
SeaStar_SM_LogoCard.png
Record Monthly Enrollment Achieved in SeaStar Medical’s Pivotal Adult AKI Trial
November 01, 2024 08:30 ET | SeaStar Medical Holding Corporation
DENVER, Nov. 01, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
SeaStar_SM_LogoCard.png
SeaStar Medical Adds Second Hospital Customer for QUELIMMUNE
October 31, 2024 08:30 ET | SeaStar Medical Holding Corporation
DENVER, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
logo.png
Positive Preliminary Results Demonstrate Autonomix’s Proprietary RF Ablation Technology’s Ability to Reduce Opioid Use in Ongoing Human Clinical Trial
October 28, 2024 08:00 ET | Autonomix Medical, Inc.
100% of the responder group went to zero opioid use at 4-6 weeks post-procedure Up to 75% of late-stage pancreatic cancer patients are prescribed opioids and data suggests 20% are at risk for abuse...